Newsroom Archive | Enterra Medical, Inc.

Enterra Medical Introduces the new, FDA approved Enterra ReliaStim^® as the Next Step Toward the Future of GES Therapy

Enterra Medical, Inc., today introduced Enterra ReliaStim, a new stimulation lead designed to make Gastric Electrical Stimulation (GES) lead placement more precise, consistent, and efficient.

New hope for chronic nausea: Enterra Medical begins NAVIGATE study after gaining FDA IDE approval and Breakthrough Device designation

Enterra Medical, Inc., a leader in innovative treatments for gastrointestinal disorders, has initiated the NAVIGATE study to evaluate the safety and effectiveness of Gastric Electrical Stimulation (GES) as a treatment for patients with chronic nausea that have normal gastric emptying.

Enterra^® II System—an Advanced Treatment for Gastroparesis—Receives FDA Approval for MR Conditional Use

Enterra Medical, Inc., an innovator in treatments for people living with gastroparesis, announced today that the Enterra II System has been granted MR Conditional approval from the United States Food and Drug Administration (FDA).

Enterra Medical Introduces the new, FDA approved Enterra ReliaStim^® as the Next Step Toward the Future of GES Therapy

New hope for chronic nausea: Enterra Medical begins NAVIGATE study after gaining FDA IDE approval and Breakthrough Device designation

Enterra^® II System—an Advanced Treatment for Gastroparesis—Receives FDA Approval for MR Conditional Use

IMPORTANT SAFETY INFORMATION

HUMANITARIAN DEVICE